Traws Pharma

TRAW

Market cap $20.8M

Broad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa Utilizing a novel dual-strike mechanism, the proprietary combination agent has the potential to deliver a low pill burden option to manage existing and future outbreaks Interactions planned with the US Centers for Disease Control and Prevention (CDC), and ongoing with the Nigerian National Agency for Food and Drug Administration and Control (NAFDAC), and the African Medicines Agency (AMA) to fast-track clinical development, emergency manufacturing scale-up, and global access NEWTOWN, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced the advancement of a novel proprietary broad-spectrum combination anti-viral agent in its portfolio.

Private financing of up to $60M offering of common stock (with $10M upfront) and milestone-based warrants expected to support operations into Q1 2027

It's been a struggle to secure funding for hantavirus research because these viruses haven't been a priority.

Traws Pharma, Inc. (NASDAQ:TRAW) shares are up during Friday's session, trading higher by 25.86% as the company is advancing potential clinical candidates for the treatment of hantavirus infections.

NEWTOWN, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced plans to advance potential clinical candidates for the treatment of hantavirus infections.

Traws Pharma, Inc. (TRAW) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Traws Pharma, Inc. (TRAW) Q4 2025 Earnings Call Transcript

Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent, building on broad preclinical antiviral activity,

Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID ® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution; results were recapitulated in PAXLOVID ® -ineligible patients, representing a significant population with no effective treatment options

IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in strategic stockpile